Literature DB >> 23836650

CD22 ligand-binding and signaling domains reciprocally regulate B-cell Ca2+ signaling.

Jennifer Müller1, Ingrid Obermeier, Miriam Wöhner, Carolin Brandl, Sarah Mrotzek, Sieglinde Angermüller, Palash C Maity, Michael Reth, Lars Nitschke.   

Abstract

A high proportion of human B cells carry B-cell receptors (BCRs) that are autoreactive. Inhibitory receptors such as CD22 can downmodulate autoreactive BCR responses. With its extracellular domain, CD22 binds to sialic acids in α2,6 linkages in cis, on the surface of the same B cell or in trans, on other cells. Sialic acids are self ligands, as they are abundant in vertebrates, but are usually not expressed by pathogens. We show that cis-ligand binding of CD22 is crucial for the regulation of B-cell Ca(2+) signaling by controlling the CD22 association to the BCR. Mice with a mutated CD22 ligand-binding domain of CD22 showed strongly reduced Ca(2+) signaling. In contrast, mice with mutated CD22 immunoreceptor tyrosine-based inhibition motifs have increased B-cell Ca(2+) responses, increased B-cell turnover, and impaired survival of the B cells. Thus, the CD22 ligand-binding domain has a crucial function in regulating BCR signaling, which is relevant for controlling autoimmunity.

Entities:  

Keywords:  B-lymphocyte differentiation; B-lymphocyte signaling; Siglecs

Mesh:

Substances:

Year:  2013        PMID: 23836650      PMCID: PMC3725054          DOI: 10.1073/pnas.1304888110

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  37 in total

1.  CD22 serves as a receptor for soluble IgM.

Authors:  Takahiro Adachi; Satoru Harumiya; Hiromu Takematsu; Yasunori Kozutsumi; Matthias Wabl; Manabu Fujimoto; Thomas F Tedder
Journal:  Eur J Immunol       Date:  2011-11-10       Impact factor: 5.532

2.  CD22 x Siglec-G double-deficient mice have massively increased B1 cell numbers and develop systemic autoimmunity.

Authors:  Julia Jellusova; Ute Wellmann; Kerstin Amann; Thomas H Winkler; Lars Nitschke
Journal:  J Immunol       Date:  2010-03-03       Impact factor: 5.422

3.  Hyperresponsive B cells in CD22-deficient mice.

Authors:  T L O'Keefe; G T Williams; S L Davies; M S Neuberger
Journal:  Science       Date:  1996-11-01       Impact factor: 47.728

4.  CD22 is a negative regulator of B-cell receptor signalling.

Authors:  L Nitschke; R Carsetti; B Ocker; G Köhler; M C Lamers
Journal:  Curr Biol       Date:  1997-02-01       Impact factor: 10.834

5.  Grb2 regulates B-cell maturation, B-cell memory responses and inhibits B-cell Ca2+ signalling.

Authors:  Jochen A Ackermann; Daniel Radtke; Anna Maurberger; Thomas H Winkler; Lars Nitschke
Journal:  EMBO J       Date:  2011-03-22       Impact factor: 11.598

6.  Homomultimeric complexes of CD22 in B cells revealed by protein-glycan cross-linking.

Authors:  Shoufa Han; Brian E Collins; Per Bengtson; James C Paulson
Journal:  Nat Chem Biol       Date:  2005-06-12       Impact factor: 15.040

7.  Masking of CD22 by cis ligands does not prevent redistribution of CD22 to sites of cell contact.

Authors:  Brian E Collins; Ola Blixt; Alexis R DeSieno; Nicolai Bovin; Jamey D Marth; James C Paulson
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-12       Impact factor: 11.205

8.  A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP.

Authors:  G M Doody; L B Justement; C C Delibrias; R J Matthews; J Lin; M L Thomas; D T Fearon
Journal:  Science       Date:  1995-07-14       Impact factor: 47.728

9.  Inhibition of the B cell by CD22: a requirement for Lyn.

Authors:  K G Smith; D M Tarlinton; G M Doody; M L Hibbs; D T Fearon
Journal:  J Exp Med       Date:  1998-03-02       Impact factor: 14.307

10.  Regulation of B cell functions by the sialic acid-binding receptors siglec-G and CD22.

Authors:  Julia Jellusova; Lars Nitschke
Journal:  Front Immunol       Date:  2012-01-11       Impact factor: 7.561

View more
  37 in total

1.  Nanoscale organization and dynamics of the siglec CD22 cooperate with the cytoskeleton in restraining BCR signalling.

Authors:  Francesca Gasparrini; Christoph Feest; Andreas Bruckbauer; Pieta K Mattila; Jennifer Müller; Lars Nitschke; Dennis Bray; Facundo D Batista
Journal:  EMBO J       Date:  2015-12-15       Impact factor: 11.598

2.  CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases : English version.

Authors:  T Tsubata
Journal:  Z Rheumatol       Date:  2017-03       Impact factor: 1.372

Review 3.  [CD22 and CD72 are inhibitory receptors dominantly expressed in B lymphocytes and regulate systemic autoimmune diseases. German version].

Authors:  T Tsubata
Journal:  Z Rheumatol       Date:  2016-02       Impact factor: 1.372

Review 4.  The role of CD22 and Siglec-G in B-cell tolerance and autoimmune disease.

Authors:  Jennifer Müller; Lars Nitschke
Journal:  Nat Rev Rheumatol       Date:  2014-04-29       Impact factor: 20.543

Review 5.  Cytoskeletal control of B cell responses to antigens.

Authors:  Pavel Tolar
Journal:  Nat Rev Immunol       Date:  2017-07-10       Impact factor: 53.106

Review 6.  Siglec-mediated regulation of immune cell function in disease.

Authors:  Matthew S Macauley; Paul R Crocker; James C Paulson
Journal:  Nat Rev Immunol       Date:  2014-09-19       Impact factor: 53.106

Review 7.  Sialic acids and autoimmune disease.

Authors:  Vinay S Mahajan; Shiv Pillai
Journal:  Immunol Rev       Date:  2016-01       Impact factor: 12.988

8.  CXCR4 signaling and function require the expression of the IgD-class B-cell antigen receptor.

Authors:  Martin Becker; Elias Hobeika; Hassan Jumaa; Michael Reth; Palash C Maity
Journal:  Proc Natl Acad Sci U S A       Date:  2017-05-01       Impact factor: 11.205

Review 9.  The Glycoscience of Immunity.

Authors:  Julie Y Zhou; Douglas M Oswald; Kelsey D Oliva; Lori S C Kreisman; Brian A Cobb
Journal:  Trends Immunol       Date:  2018-05-11       Impact factor: 16.687

10.  CD22 Promotes B-1b Cell Responses to T Cell-Independent Type 2 Antigens.

Authors:  Karen M Haas; Kristen L Johnson; James P Phipps; Cardinal Do
Journal:  J Immunol       Date:  2018-01-26       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.